Dyne Therapeutics Inc at Chardan Genetic Medicines Conference Transcript
Good morning, and welcome to day two of our sixth annual Chardan genetic medicines conference. It's my pleasure to welcome our first guests this morning from Dyne Therapeutics. CEO Josh Brumm and CMO, Dr. Wildon Farwell. Thank you.
So let's get started, Josh, maybe to start, provide just a couple minutes of overview of Dyne for those who are new to the story.
Yes. First of all, thanks for the invitation to be here today. It's great to be here. And [you have just] tell the story with Wildon. This is an exciting time for Dyne. We have said that this year would all be about really get into the clinic and two programs. And we're very excited as a company to be able to have the opportunity to bring two programs for discovery into clinic in just under three years, and our DM1 and DMD programs. So that's exactly where we are.
Earlier in September, we talked about the deliver study in DMD for exon 51 with DYNE-251. We talked about the achieve study in DM1 with DYNE-101. And we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
